NCT02454933 - Study of AZD9291 Plus MEDI4736 Versus AZD9291 Monotherapy in NSCLC After Previous EGFR TKI Therapy in T790M Mutation Positive Tumours | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

July 15, 2015

Primary Completion Date

August 21, 2017

Study Completion Date

June 21, 2023

Conditions

Locally Advanced or Metastatic EGFR T790M+ NSCLC

Interventions

DRUG

AZD9291

Once daily tablet 80 mg

DRUG

MEDI4736

10mg/kg q2w (IV) infusion

Trial Locations (13)

Research Site, Taipei

Research Site, Seongnam-si

Research Site, Incheon

Research Site, Taichung

Research Site, Daegu

Research Site, Ulsan

Research Site, Busan

Research Site, Kaohsiung City

Research Site, Toronto

Research Site, Jinju

Research Site, Seoul

Research Site, Seoul

Research Site, Seoul